Ramaprasad  Srinivasan, M.D., Ph.D.
Ramaprasad Srinivasan, M.D., Ph.D.
Staff Clinician
Head, Molecular Cancer Therapeutics Section

Center for Cancer Research
National Cancer Institute

Building 10 - Hatfield CRC, Room 1-5940
Bethesda, MD 20892
301-496-6353

Dr. Srinivasan is a Staff Clinician in the Urologic Oncology Branch, National Cancer Institute (NCI). He obtained his M.D., from the Bangalore Medical College in India and completed his Ph.D., in biomedical sciences at the University of Texas MD Anderson Cancer Center in Houston. He came to NCI in 1999 after completing his Internal Medicine Residency training at the University of Texas Health Science Center-Houston, to pursue a fellowship in Medical Oncology/Hematology. After completing his fellowship, he joined the Urologic Oncology Branch, where he is developing treatment strategies and clinical trials for patients with both hereditary and non-hereditary forms of kidney cancer. He is currently investigating a variety of newer 'targeted' agents in clear cell and papillary kidney cancer, as well as hereditary kidney cancer syndromes such as von Hippel-Lindau, hereditary leiomyomatosis and renal cell cancer and hereditary papillary renal cell cancer (HPRC)

Areas of Expertise
kidney cancer
Selected Publications
  1. Linehan WM, Srinivasan R, Garcia JA.
    Semin. Oncol.. 40: 511-20, 2013. [ Journal Article ]
  2. Choueiri TK, Vaishampayan U, Rosenberg JE, Logan TF, Harzstark AL, Bukowski RM, Rini BI, Srinivas S, Stein MN, Adams LM, Ottesen LH, Laubscher KH, Sherman L, McDermott DF, Haas NB, Flaherty KT, Ross R, Eisenberg P, Meltzer PS, Merino MJ, Bottaro DP, Linehan WM, Srinivasan R.
    J. Clin. Oncol.. 31: 181-6, 2013. [ Journal Article ]
  3. Shuch B, Vourganti S, Ricketts CJ, Middleton L, Peterson J, Merino MJ, Metwalli AR, Srinivasan R, Linehan WM.
    J. Clin. Oncol.. 32: 431-7, 2014. [ Journal Article ]
  4. Shuch B, Linehan WM, Srinivasan R.
    Expert Rev Anticancer Ther. 13: 711-9, 2013. [ Journal Article ]
  5. Liu NW, Sanford T, Srinivasan R, Liu JL, Khurana K, Aprelikova O, Valero V, Bechert C, Worrell R, Pinto PA, Yang Y, Merino M, Linehan WM, Bratslavsky G.
    Clin. Cancer Res.. 19: 42-9, 2013. [ Journal Article ]

Dr. Srinivasan is a Staff Clinician in the Urologic Oncology Branch, National Cancer Institute (NCI). He obtained his M.D., from the Bangalore Medical College in India and completed his Ph.D., in biomedical sciences at the University of Texas MD Anderson Cancer Center in Houston. He came to NCI in 1999 after completing his Internal Medicine Residency training at the University of Texas Health Science Center-Houston, to pursue a fellowship in Medical Oncology/Hematology. After completing his fellowship, he joined the Urologic Oncology Branch, where he is developing treatment strategies and clinical trials for patients with both hereditary and non-hereditary forms of kidney cancer. He is currently investigating a variety of newer 'targeted' agents in clear cell and papillary kidney cancer, as well as hereditary kidney cancer syndromes such as von Hippel-Lindau, hereditary leiomyomatosis and renal cell cancer and hereditary papillary renal cell cancer (HPRC).

Summary

Dr. Srinivasan is a Staff Clinician in the Urologic Oncology Branch, National Cancer Institute (NCI). He obtained his M.D., from the Bangalore Medical College in India and completed his Ph.D., in biomedical sciences at the University of Texas MD Anderson Cancer Center in Houston. He came to NCI in 1999 after completing his Internal Medicine Residency training at the University of Texas Health Science Center-Houston, to pursue a fellowship in Medical Oncology/Hematology. After completing his fellowship, he joined the Urologic Oncology Branch, where he is developing treatment strategies and clinical trials for patients with both hereditary and non-hereditary forms of kidney cancer. He is currently investigating a variety of newer 'targeted' agents in clear cell and papillary kidney cancer, as well as hereditary kidney cancer syndromes such as von Hippel-Lindau, hereditary leiomyomatosis and renal cell cancer and hereditary papillary renal cell cancer (HPRC)

Areas of Expertise
kidney cancer

Clinical Trials

Publications

Selected Publications
  1. Linehan WM, Srinivasan R, Garcia JA.
    Semin. Oncol.. 40: 511-20, 2013. [ Journal Article ]
  2. Choueiri TK, Vaishampayan U, Rosenberg JE, Logan TF, Harzstark AL, Bukowski RM, Rini BI, Srinivas S, Stein MN, Adams LM, Ottesen LH, Laubscher KH, Sherman L, McDermott DF, Haas NB, Flaherty KT, Ross R, Eisenberg P, Meltzer PS, Merino MJ, Bottaro DP, Linehan WM, Srinivasan R.
    J. Clin. Oncol.. 31: 181-6, 2013. [ Journal Article ]
  3. Shuch B, Vourganti S, Ricketts CJ, Middleton L, Peterson J, Merino MJ, Metwalli AR, Srinivasan R, Linehan WM.
    J. Clin. Oncol.. 32: 431-7, 2014. [ Journal Article ]
  4. Shuch B, Linehan WM, Srinivasan R.
    Expert Rev Anticancer Ther. 13: 711-9, 2013. [ Journal Article ]
  5. Liu NW, Sanford T, Srinivasan R, Liu JL, Khurana K, Aprelikova O, Valero V, Bechert C, Worrell R, Pinto PA, Yang Y, Merino M, Linehan WM, Bratslavsky G.
    Clin. Cancer Res.. 19: 42-9, 2013. [ Journal Article ]

Biography

Dr. Srinivasan is a Staff Clinician in the Urologic Oncology Branch, National Cancer Institute (NCI). He obtained his M.D., from the Bangalore Medical College in India and completed his Ph.D., in biomedical sciences at the University of Texas MD Anderson Cancer Center in Houston. He came to NCI in 1999 after completing his Internal Medicine Residency training at the University of Texas Health Science Center-Houston, to pursue a fellowship in Medical Oncology/Hematology. After completing his fellowship, he joined the Urologic Oncology Branch, where he is developing treatment strategies and clinical trials for patients with both hereditary and non-hereditary forms of kidney cancer. He is currently investigating a variety of newer 'targeted' agents in clear cell and papillary kidney cancer, as well as hereditary kidney cancer syndromes such as von Hippel-Lindau, hereditary leiomyomatosis and renal cell cancer and hereditary papillary renal cell cancer (HPRC).